Inhibitex to Present at Two Upcoming Investor Conferences
April 26 2011 - 2:00PM
Business Wire
Inhibitex, Inc. (NASDAQ:INHX), a biopharmaceutical company
focused on developing products to treat and prevent serious
infectious diseases, announced that Russell H. Plumb, President and
Chief Executive Officer, is scheduled to present an overview of the
company and its pipeline of differentiated antiviral compounds at
the following two investor conferences in May:
-- The Deutsche Bank Securities 36th Annual Health Care
Conference on May 2, 2011 at 9:20 AM EDT. The conference is being
held at the Intercontinental Hotel in Boston.
-- 10th Annual JMP Securities Research Conference on May 10,
2011 at 3:00 PM PDT. The conference is being held at the Ritz
Carlton Hotel in San Francisco.
About Inhibitex
Inhibitex, Inc., is a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s clinical-stage pipeline includes FV-100, a
nucleoside inhibitor in Phase 2 for the treatment of shingles, and
INX-189, a nucleotide polymerase inhibitor in Phase 1b for the
treatment of chronic hepatitis C infections. The Company also has
additional HCV nucleotide polymerase inhibitors in preclinical
development and has licensed the use of its proprietary MSCRAMM®
protein platform to Pfizer for the development of staphylococcal
vaccines. For additional information about the Company, please
visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024